Journal of Vaccines & Vaccination

The safety of yellow fever vaccine, international experience for different cases

13^th Annual Congress on Vaccines, Therapeutics & Travel Medicine: Influenza & Infectious diseases

December 01-02, 2016 Atlanta, USA

Merita Kucuku

National Agency for Medicines & Medical Devices, Albania

Scientific Tracks Abstracts: J Vaccines Vaccin

Abstract:

Yellow fever virus is from family flaviviridae and is endemic in African countries and Latin America. Over 900 million people are living in endemic area and are risked from infection of yellow fever. Illness ranges in severity from a self-limited febrile illness to severe liver disease with bleeding and is diagnosed based on symptoms, physical findings, laboratory testing and travel history, including the possibility of exposure to infected mosquitoes. There is no specific treatment for yellow fever; care is based on symptoms. The steps necessary to prevent yellow fever virus infection includes using insect repellent, wearing protective clothing and getting vaccinated. Yellow fever vaccine is recommended for endemic countries and over 500 million people are vaccinated with yellow fever vaccine 17D. The countries which are not endemic are recommended to vaccinate people in cases of travelling in endemic areas to avoid the importation of yellow fever virus and epidemic outbreak in country. The cases of yellow fever are reported in countries free of yellow. According the data based on the different studies in different countries the Yellow Fever 17D and 17DD is very safe vaccines and effective against illness and the best way for preventing yellow fever infection.

Biography :

Merita Kucuku is currently working in National Agency for Medicines and Medical Devices of Albania for safety, control and efficacy of vaccines. She was the Head of National Regulatory Authority of Vaccines & Immunobiological Products of Albania from 2006-2012. She has completed her MSc in 2006 and PhD on University of Tirana in Faculty of Natural Science Tirana Albania in 2010. She is a Member of Abortion WG for safety of the Global Alignment of Immunization Safety in Pregnancy (GAIA Project), Member of working group for case definiton-vasculitis, arranged from AIFA-Italy & Brighton Collaboration Geneva Switzerland and Member of reference group for the first five neonatal & first five obstetric case definitions related to immunization in pregnancy.

Email: emkoni@hotmail.com